Palvella Therapeutics’ (PVLA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research note published on Friday morning,Benzinga reports. The firm currently has a $38.00 target price on the stock.

Separately, Cantor Fitzgerald started coverage on shares of Palvella Therapeutics in a report on Wednesday, December 18th. They set an “overweight” rating for the company.

Palvella Therapeutics Stock Down 2.0 %

Shares of PVLA stock opened at $13.97 on Friday. Palvella Therapeutics has a 1 year low of $6.20 and a 1 year high of $22.32. The firm has a market capitalization of $18.44 million, a P/E ratio of -1.15 and a beta of 0.67.

Insiders Place Their Bets

In related news, Director George M. Jenkins purchased 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The shares were purchased at an average cost of $12.93 per share, with a total value of $51,720.00. Following the purchase, the director now owns 180,671 shares of the company’s stock, valued at $2,336,076.03. This represents a 2.26 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 6.39% of the company’s stock.